VEGFA and renal cell carcinoma: Patients with advanced RCC develop new metastatic lesions up to 10–30% despite being treated with new drugs, including vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) or targeted therapies [3, 4].